News19.01.2024
DvH Ventures backs MedTech-startup OneTwenty to revolutionize diabetes care
ZURICH, January 2024 – OneTwenty AG, the innovative diabetes tech startup, is proud to announce the successful closure of its first funding round in December 2023. The investment was led by renowned health technology VC Dieter von Holtzbrinck Ventures (dvhventures.de), with notable contributions from Tiny Supercomputer Investment Company (tiny.vc) and seasoned angel investor and diabetes care manager, Tim Juergens.
This significant capital injection propels OneTwenty to the forefront of diabetes management technology, fueling the continued development and deployment of their groundbreaking algorithmic solutions. OneTwenty's promising autonomous closed-loop system, designed to seamlessly integrate with medical devices such as insulin pumps, smart pens, and blood glucose sensors, significantly enhances the quality of life for individuals living with diabetes through better dosing and treatment recommendations and automation.
"Daily management of diabetes is a challenging task, often hindered by the rigorous demands of tracking and adjusting to dynamic needs of the body. Our advanced machine learning solutions demystify the body's responses to daily activities, medication and stressors, offering a new era of truly personalized diabetes care."
The secured capital will be strategically invested in the commercialization and robust concurrent execution of integration projects for OneTwenty’s forthcoming medtech and pharmaceutical partnerships. Following a series of successful pilot projects in 2023, the company is recently actively engaging with industry leaders to establish long-term licensing agreements.
"The confidence placed in us by DvH Ventures, Tiny, and Tim Juergens, especially in a year witnessing a significant two-digit downturn in health tech investment, is a testament to the potential of our solutions. We've doubled our team post-investment and are accelerating our growth trajectory to meet the increasing demand for our innovative technology."
It is OneTwenty’s first investment round. Up until this point, the company's operations had been self-financed by its founders' initial capital and early revenue streams.This new phase of external funding signifies an important milestone, reflecting the team's ambitious vision for the company's future.
About OneTwenty
OneTwenty is a Zurich-based startup at the vanguard of diabetes technology. With a mission to elevate diabetes care, the company specializes in developing AI-driven algorithms that enhance the functionality of diabetes devices. OneTwenty's proprietary technology stands as the first in the market capable of navigating the intricacies of human metabolism, offering an autonomous and streamlined approach to diabetes management.
In 2023, well-known personalities from the diabetes technology and machine learning scene joined OneTwenty and have been supporting the team since then: Prof. Lutz Heinemann (Managing Editor of the Journal of Diabetes Science and Technology), Fredrik Debong (cofounder mySugr), and Nicole Büttner (cofounder Merantix Momentum).
For more information, please contact:
Michael Rottmann
michael@onetwenty.ai
www.onetwenty.ai